Kirkland, Washington, United States InterVest appeared to be the Corporate Investor, which was created in 1987. The company was established in North America in United States. The main office of represented Corporate Investor is situated in the Kirkland.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The real fund results show that this Corporate Investor is 5 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2019. The fund is constantly included in 2-6 investment rounds annually.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the InterVest, startups are often financed by Solidus Investment, SBI Investment, Mirae Asset Venture Investment. The meaningful sponsors for the fund in investment in the same round are Mirae Asset Venture Investment, Solidus Investment, Smilegate Investment. In the next rounds fund is usually obtained by Wooshin Venture Investment Corp., Solidus Investment, Smilegate Investment.
The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. For fund there is no match between the location of its establishment and the land of its numerous investments - South Korea. Among the most popular fund investment industries, there are Biotechnology, Pharmaceutical. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ImmunoMet Therapeutics, Aerodyne Group, Neuraly.
Related Funds
| Fund Name | Location |
| Aon plc | England, London, United Kingdom |
| B-ForeCapital | - |
| Beihou Yijiu Investment Management | Beijing, Beijing, China |
| Beijing Ant Cell Tour International Travel Service | Beijing, Beijing, China |
| Blue Otus | - |
| Color Capital | Oregon, Portland, United States |
| CS Capital | China, Shanghai |
| Duff, Ackerman and Goodrich | California, San Francisco, United States |
| European Commission | Belgium, Brussels, Brussels Hoofdstedelijk Gewest |
| FIWARE | Berlin, Berlin, Germany |
| GeneChem Inc. | Daejeon, South Korea, Taejon-jikhalsi |
| Humphrey Enterprises LLC | Boston, Massachusetts, United States |
| IXcore | France, Ile-de-France, Marly-le-roi |
| Linghao Touzi | China, Shanghai |
| NorthBay Solutions | Cambridge, Massachusetts, United States |
| SITAM | - |
| The Broe Group | Colorado, Denver, United States |
| TiE LaunchPad | California, Sunnyvale, United States |
| TSK | Asturias, Gijón, Spain |
| Zhuhai Zhongle | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Wecover Platforms | $6M | 11 Jun 2024 | Cambridge, Massachusetts, United States | ||
Feature | $1M | 26 May 2024 | Los Angeles, California, United States | ||
WIRobotics | $3M | 21 Apr 2023 | Yongin, Ch'ungch'ong-namdo, South Korea | ||
Dot | $12M | 01 Sep 2022 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
Finda | $3M | 22 Jul 2022 | South Korea, Gyeonggi-do, South Korea | ||
iN Therapeutics | $22M | 07 Feb 2022 | Kyonggi-do, Gyeonggi-do, South Korea | ||
N.THING | $15M | 30 Sep 2021 | South Korea, Gyeonggi-do, South Korea | ||
H2O Hospitality | $26M | 07 Sep 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
Mobilint | $7M | 31 Jul 2021 | Yeoksamdong, Seoul-t'ukpyolsi, South Korea |
– Standigm closed a $44.5m pre-IPO funding round co-led by SKS PE and Daishin Private Equity.
– The round was joined by new investors in banking and technology, including SKS PE, Daishin Private Equity, InterVest, KDB Bank, and Asset One.
– Standigm’s second-largest shareholder, SK holdings, also participated through acquiring existing shares.
– The closing marks the last round of funding before Standigm goes to its planned initial public offering (IPO) on the Korea Exchange (KRX) later this year.
– Founded in 2015, Standigm has achieved full-stack AI-driven industrializing drug discovery.
– Standigm’s AI platforms range from new drug target discovery to novel drug lead generation, enabling pharmaceutical companies to save time and cost.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Wecover Platforms | $6M | 11 Jun 2024 | Cambridge, Massachusetts, United States | ||
Feature | $1M | 26 May 2024 | Los Angeles, California, United States | ||
WIRobotics | $3M | 21 Apr 2023 | Yongin, Ch'ungch'ong-namdo, South Korea | ||
Dot | $12M | 01 Sep 2022 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
Finda | $3M | 22 Jul 2022 | South Korea, Gyeonggi-do, South Korea | ||
iN Therapeutics | $22M | 07 Feb 2022 | Kyonggi-do, Gyeonggi-do, South Korea | ||
N.THING | $15M | 30 Sep 2021 | South Korea, Gyeonggi-do, South Korea | ||
H2O Hospitality | $26M | 07 Sep 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
Mobilint | $7M | 31 Jul 2021 | Yeoksamdong, Seoul-t'ukpyolsi, South Korea |
